Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Google Inc (GOOG) vs Twist Bioscience Corp (TWST) Price & Performance

Google IncTrade
Twist Bioscience CorpTrade

Price performance (Past 24H)

Key statistics

Google Inc vs Twist Bioscience Corp — how do they compare? Google Inc trades at $342.56 (market cap $4.20T), while Twist Bioscience Corp trades at $124.64 (market cap $7.72B). The key difference: Google Inc is far larger — about 544× Twist Bioscience Corp's market cap, and Google Inc pays a 0.26% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.

GOOGTWST
Market Cap
$4.20T$7.72B
Volume
1,511,127
Sector
TechnologyHealth
52-Week High
$399.06$124.88
52-Week Low
$200.19$24.16
Enterprise Value
$4.09T$7.65B
Dividend Yield
0.26%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Google Inc

Alphabet (GOOG) trades at $342.71, down 3.69% on the day, with technical indicators showing a bearish trend near support at $340. The company reported strong fundamentals with Q2 2026 EPS of $9.11 beating expectations, revenue growth to $402.84B in 2025, and robust profitability margins. Recent news highlights AI advancements, including Gemini reaching 1 billion users, but also regulatory scrutiny from French media.

The stock presents a compelling long-term opportunity with a consensus price target of $431.67, representing 26% upside, supported by 87% analyst buy ratings. Risks include high capital expenditure forecasts up to $205B for 2026, competitive AI pressures, and ongoing regulatory challenges. Investors should weigh strong cash flow generation against aggressive investment cycles.

Twist Bioscience Corp

Twist Bioscience (TWST) trades at $125.13, up 0.2% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported Q3 2026 revenue of $118.4 million, up 23% year-over-year, beating estimates, but posted a net loss. Revenue growth is strong, yet profitability remains elusive with negative margins. Recent news highlights an upsized $300 million public offering and expanding AI drug discovery pipeline.

Outlook is mixed: robust revenue growth and analyst optimism (78.57% buy ratings) support upside, but persistent losses, cash burn, and high valuation multiples pose significant risks. The stock's proximity to resistance at $126 suggests near-term volatility. Investors should weigh growth potential against financial sustainability concerns.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Google Inc

Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.

Read more on GOOG

About Twist Bioscience Corp

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.

Read more on TWST